Journal article
Practical guidelines on the use of paliperidone palmitate in schizophrenia
R Newton, H Hustig, R Lakshmana, J Lee, B Motamarri, P Norrie, R Parker, A Schreiner
Current Medical Research and Opinion | TAYLOR & FRANCIS LTD | Published : 2012
Abstract
Objective: Paliperidone palmitate is an atypical long-acting injectable (LAI) antipsychotic that has been approved for use in the US, EU, Australia and numerous other countries for acute and maintenance therapy of schizophrenia. LAI antipsychotics are often viewed as a 'last-resort' treatment for difficult-to-treat patients, however this article considers their role more broadly in the management of partial or non-adherence in schizophrenia. Method: A search of MedLine, CTR and PsychInfo was conducted to identify relevant publications and clinical trials (search term 'paliperidone palmitate', up to December 2010). The findings were discussed in a number of teleconferences and the manuscript ..
View full abstractGrants
Funding Acknowledgements
[ "Funding for writing group meetings (i.e., travel and meeting costs) was provided by Janssen Cilag Pty Ltd.", "B. M. has disclosed that he is a consultant to Janssen Cilag and is on the steering committee for the company's educational group. He has also received grants from Janssen. R. P. has disclosed receiving sponsorship from Janssen Cilag. R.N. has disclosed that he has been sponsored by Janssen Cilag and is a consultant to and on the speaker's bureau of Janssen, Eli Lilly, Astra Zeneca and Lundbeck. A. S. has disclosed that he is an employee of Janssen Cilag and holds stock in Johnson & Johnson. H. H. has disclosed that he has received sponsorship and grants from Janssen Cilag and is a consultant to and on the speaker's bureau of Janssen, Eli Lilly, Pfizer, Wyeth, Astra Zeneca, and Servier. He is also an advisor to Lundbeck, Janssen and Pfizer. J.L. has disclosed that he received sponsorship from Janssen Cilag and funding for grant research and consultancy from Janssen and Eli Lilly. P.D.N. has disclosed receiving sponsorship from Janssen Cilag and Servier, is a consultant to Janssen, Eli Lilly, Lundbeck and Novartis and is on Lilly's speaker's bureau. R. L. has disclosed that he is a consultant to Eli Lilly and Janssen Cilag, and is on the speaker's bureau of Eli Lilly, Janssen, and Astra Zeneca. CMRO peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.", "The authors thank Naomi Adam from Allori Pty Limited for medical writing support, which was funded by Janssen Cilag Pty." ]